Study protocol

Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial

David Wayne Johnson*1,2, Carmel Mary Hawley1,2, Brenda Rosser1, Elaine Beller1, Charles Thompson1, Robert G Fassett1,3, Paolo Ferrari1,4, Stephen MacDonald1,5, Eugenie Pedagogos1,6 and Alan Cass1,7

Address: 1Australian Kidney Trials Network, School of Population Health, University of Queensland, Brisbane, Australia, 2Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia, 3Department of Nephrology, Launceston Hospital, Launceston, Australia, 4Department of Renal Medicine, Fremantle Hospital, Fremantle, Australia, 5Department of Nephrology & Transplantation Services, University of Adelaide at the Queen Elizabeth Hospital, Adelaide, Australia, 6Department of Nephrology, Royal Melbourne Hospital, Melbourne, Australia and 7The George Institute for International Health, Sydney, Australia

Email: David Wayne Johnson* - david_johnson@health.qld.gov.au; Carmel Mary Hawley - carmel_hawley@health.qld.gov.au; Brenda Rosser - Brenda.Rosser@qimr.edu.au; Elaine Beller - e.beller@uq.edu.au; Charles Thompson - c.thompson3@uq.edu.au; Robert G Fassett - Rob.Fassett@dhhs.tas.gov.au; Paolo Ferrari - paolo.ferrari@health.wa.gov.au; Stephen MacDonald - stephenm@anzdata.org.au; Eugenie Pedagogos - eugenie.pedagogos@mh.org.au; Alan Cass - acass@george.org.au

* Corresponding author

Abstract

Background: The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients.

Methods/design: Inclusion criteria are adult patients with stage 4 or 5 chronic kidney disease (including dialysis patients) with significant anaemia (haemoglobin ≤ 110 g/L) for at least 3 months for which there is no clear identifiable cause and that is unresponsive to large doses of either erythropoietin (≥ 200 IU/kg/week) or darbepoetin (≥ 1 μg/kg/week). Patients will be randomized 1:1 to receive either placebo (1 tablet daily) or oxpentifylline (400 mg daily) per os for a period of 4 months. During this 4 month study period, haemoglobin measurements will be performed monthly. The primary outcome measure will be the difference in haemoglobin level between the 2 groups at the end of the 4 month study period, adjusted for baseline values. Secondary outcome measures will include erythropoiesis stimulating agent dosage, Key’s index (erythropoiesis stimulating agent dosage divided by haemoglobin concentration), and blood transfusion requirement.

Discussion: This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their chronic kidney disease patients determine whether oxpentifylline represents a safe and effective strategy for treating erythropoiesis stimulating agent resistance in chronic kidney disease.

Trial Registration: Australian New Zealand Clinical Trials Registry Number ACTRN12608000199314.

Published: 1 August 2008

BMC Nephrology 2008, 9:8 doi:10.1186/1471-2369-9-8

This article is available from: http://www.biomedcentral.com/1471-2369/9/8

© 2008 Johnson et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
The development of erythropoiesis stimulatory agents (ESA), such as recombinant human erythropoietin (EPO) and darbepoetin alpha (DPO), has resulted in substantial health benefits for patients with end-stage kidney disease (ESKD), including improved quality of life, reduced blood transfusion requirements, decreased left ventricular mass, diminished sleep disturbance and enhanced exercise capacity [1,2]. Unfortunately, a considerable proportion of such patients exhibit a suboptimal haematologic response to ESA, which in most cases is due to inadequate iron supply to the erythron [3]. Other known causes of ESA-resistance include infection, neoplasia, severe hyperparathyroidism, aluminium intoxication, vitamin B₁₂ deficiency, folate deficiency, inadequate dialysis, myelosuppressive agents, haemoglobinopathies, myelodysplasia and antibody-mediated pure red cell aplasia [4]. However, even after exclusion of these conditions, a significant minority (approximately 10%) of patients exhibit ESA-resistant anaemia and have been shown to have greatly increased morbidity and mortality [4]. Inhibition of erythropoiesis by cytokines, such as tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) may play an important role in these patients [5].

Although there is no currently effective treatment for patients with ESA-resistant anaemia, oxpentifylline (pentoxyfylline) may represent a promising novel therapeutic strategy. Oxpentifylline has been used for more than twenty years in the treatment of peripheral and cerebral vascular diseases because of its potent haemorrhheological properties, which include preservation of erythrocyte water and cation content [6,7]. The drug has subsequently been found to exhibit important anti-inflammatory properties, including anti-apoptotic, anti-oxidant, anti-TNF-α and anti-IFN-γ actions [8-11]. These actions appear to be mediated via inhibition of phosphodiesterase [12]. Two small, prospective, non-randomized studies have demonstrated that oxpentifylline may significantly improve haemoglobin levels in chronic kidney disease patients with ESA-resistant anaemia (vide infra) [13,14] Navarro et al [14] treated 7 anaemic patients with advanced chronic kidney disease (CKD) (creatinine clearance < 30 mL/min) with oxpentifylline (400 mg daily per os) for 6 months. Haemoglobin levels significantly increased from 99 ± 5 to 106 ± 6 g/L (p < 0.01), whilst serum TNF-α concentrations decreased from 623 ± 366 to 562 ± 358 pg/ml (p < 0.01). No changes were observed in untreated controls. Similarly, Cooper and associates [13] administered oxpentifylline (400 mg daily per os) for 4 months to 16 ESKD patients with EPO-resistant anaemia (defined as a haemoglobin level < 107 g/L for 6 months before treatment and an EPO dose ≥ 12,000 IU/week). Among the 12 patients who completed the study, mean haemoglobin concentration increased from 95 ± 9 to 117 ± 10 g/L (p = 0.0001), whilst ex vivo T cell generation of TNF-α and IFN-γ were significantly reduced.

Hepcidin may also play a role in ESA-resistant anaemia. This agent is produced by hepatocytes and secreted into the blood in response to iron status, anaemia, hypoxia and pro-inflammatory cytokines, especially IL-6 [15-17] and IL-1 [18]. Recently published data suggests that hepcidin binds to ferroportin (FPN1), a cellular iron exporter, resulting in internalisation and loss of function [19]. FPN1 is highly expressed in macrophages of the reticuloendothelial system and enterocytes in the duodenum and mediates iron release. In macrophages, the binding of hepcidin to FPN1 and its subsequent internalisation would result in iron accumulation within the cell and less release of iron. Patients with CKD may have elevated levels of IL-1, IL-6 and TNF-α [20,21]. It is possible that elevated levels of these cytokines in CKD increase hepcidin production and reduce iron release from macrophages in the bone marrow resulting in reduced availability of iron for erythropoiesis. In fact, prohepcidin was found to accumulate in renal insufficiency [22,23].

In most signaling pathways involving TNF-α and IL-6, IL-6 is a downstream component from TNF via nuclear factor kappa B [24]. Thus, interference with TNF-α production can interfere with IL-6 signalling. In experimental models, oxpentifylline has been shown to reduce IL-6 expression [25-27].

The available studies suggest that oxpentifylline may represent a significant advance in the treatment of ESA-resistant anaemia in chronic kidney disease, but they are limited by their lack of adequate controls and the associated potential for selection, observer and co-intervention biases. A prospective, randomized, double-blind, placebo-controlled trial is required to definitively test the hypothesis that oxpentifylline corrects ESA-resistant anaemia in chronic kidney patients. This study also offers the opportunity to explore the role of the novel peptide, hepcidin, as a possible mediator of iron availability and ESA-resistance.

Methods/design
Ethics approval for the Hemoglobin elevation in Erythropoietin Resistance with Oxpentifylline (HERO) trial has been obtained from the local Institutional Ethics Committee in all participating centres prior to study initiation and patient enrolment. The study will be performed in accordance with the 2000 Edinburgh, Scotland Revision of the Declaration of Helsinki, the National Health and Medical Research Committee (NHMRC) Statement on Human Experimentation, Joint NHMRC/AVCC Statement and Guidelines on Research Practice, applicable ICH guidelines and the Therapeutic Goods Administra-
tion (TGA) – Note for guidance on good clinical practice (CPMP/ICH/135/95) annotated with TGA. Application under the Clinical Trials Notification (CTN) scheme will be required for this protocol.

**Participants**

The study population includes adults (18 years or over) with stage 4 or 5 CKD (on dialysis or estimated GFR < 30 ml/min/1.73 m²) who are able to give informed consent and who have a haemoglobin concentration < 110 g/L for at least 3 months in spite of EPO dosage ≥ 200 IU/kg/week or DPO dosage ≥ 1 μg/kg/week for at least 1 month. Patients will be recruited by local investigators from participating renal units (outpatients and dialysis units) throughout Australia and New Zealand. The multicentre nature of the study will greatly enhance the generalisability of the trial.

Exclusion criteria include:

1. Patients with a history of psychological illness or condition which interferes with their ability to understand or comply with the requirements of the study.
2. Pregnancy or breast-feeding.
3. Known hypersensitivity to, or intolerance of, oxpentifylline or other methylxanthines, such as caffeine, theophylline or theobromine.
4. Active peptic ulcer disease.
5. Absolute or functional iron deficiency (ferritin < 100 μg/L and/or transferrin saturation < 20%).
6. Vitamin B₁₂ or folate deficiency.
7. Parathyroid hormone level > 100 pmol/L.
8. Serum aluminium > 2 μmol/L.
9. Urea reduction ratio < 65% or single pool Kt/V < 1.0 (haemodialysis patients) or total weekly Kt/V < 1.7 (peritoneal dialysis patients).
10. Presence of systemic haematological disease (including antibody-mediated pure red cell aplasia) or known haemoglobinopathy
11. Major surgery, infection, acute myocardial infarction or malignancy within the last 3 months.
12. Melatonin treatment, androgen therapy or blood transfusion within the previous month.

13. Vitamin C therapy at dose greater than 100 mg/day or at a dose which has changed within the last 3 months.

14 Haemorrhagic stroke or severe haemorrhage within the last 3 months.

**Study design**

The study is an investigator-initiated, prospective, double-blind, randomized, placebo-controlled phase 3 trial. Patients will be randomised to one of two treatment groups in equal proportion (Fig. 1). To ensure adequate concealment of allocation, the randomization will be performed using a central computer and web-based link to the central database provided through the Australasian Kidney Trials Network (AKTN). Patients will be randomised in permuted blocks with stratification for centre and disease stage/dialysis type.

**Experimental intervention**

The experimental intervention will be oxpentifylline (400 mg daily per os; Trental®, Sanofi-Aventis, Sydney, Australia). Oxpentifylline is registered in Australia for treatment of intermittent claudication on the basis of chronic arterial occlusive disease of the limbs. The standard dose is 400 mg three times daily. The dose of oxpentifylline selected for this study (400 mg daily) is lower than the standard dose because the drug may accumulate in renal failure. Moreover, this dose has been shown to be efficacious without significant side effects in 23 ESKD patients studied by Cooper et al [13] and Navarro et al [14].

---

**Figure 1**

Schema for the HERO Trial.
Control intervention
The control intervention will be placebo (1 tablet daily per os).

Concurrent treatments
Iron supplementation will be performed according to usual protocol (note that randomisation will be stratified for centre). Vitamin B and folic acid supplementation are permitted. Melatonin and androgen therapy are prescribed during the study period. If the patient is taking vitamin C, the daily dose will be kept constant throughout the study period. Erythropoietin (EPO) or darbepoetin (DPO) dosages will not be increased during the study, and will only be reduced if haemoglobin levels rise above 125 g/L.

Blinding
Patients, investigators and outcome assessors will be blinded to the treatment allocation.

Outcome measures
The primary outcome measure will be the difference in haemoglobin concentration between the oxpentifylline and control groups at the end of the 4 month study period.

Secondary outcome measures include:

a. Difference in the dosage of erythropoiesis stimulating agents (ESA; either erythropoietin or darbepoetin) between the oxpentifylline and control groups at the end of the 4 month study period.

b. Difference in Key's index (ESA dosage divided by haemoglobin concentration) between the oxpentifylline and control groups at the end of the 4 month study period.

c. Difference in frequency of blood transfusion requirements between the oxpentifylline and control groups during the 4 month study period.

d. Occurrence of adverse events in the oxpentifylline and control groups during the 4 month study period.

Exploratory outcome measures that will be studied include the differences in serum concentrations of hepcidin and biomarkers of inflammation (TNF-α, interferon-γ, IL-6 and IL-1) and oxidative stress (isoprostanes, protein carbonyls, plasma catalase and glutathione peroxidase activity) between the oxpentifylline and control groups at the end of the 4 month trial.

Clinical assessment of outcome
Full blood counts will be measured monthly, as per usual clinical practice. Iron studies will be measured every 2 months. Patients will receive a medical review every 2 months. An individual patient's participation in the study will cease at the end of the 4 month study period. If, before this time, the patient experiences severe anaemia (< 65 g/L), symptomatic anaemia or the patient's attending physician believes that additional therapy is required (eg blood transfusion), they will be considered to have reached an end-point and will be withdrawn from study medication, but will still have blood counts measured monthly and followed for study outcomes.

The number and proportion of subjects who report treatment-emergent adverse events will be summarized for each treatment group. Treatment emergent events include events that start on or after Day 0 of the study [that is the first day of Study Drug administration], and were not present at baseline, or were present at baseline, but increased in severity after the start of the study. The Medical Dictionary for Regulatory Activities [MedDRA] Terminology will be used to classify all adverse events with respect to System Organ Class [SOC], high level group term (HLGT), and preferred term.

Sample size calculations
Prospective power calculations based on unpaired t-test comparisons indicate that the study will have adequate statistical power (90% probability) to detect a clinically significant increase in haemoglobin concentration of 10 g/L, assuming alpha = 0.05 and a population standard deviation of 12 g/L, if 62 patients were recruited in the study (31 in each group). Allowing for a 5% drop-out rate and a 20% non-compliance rate, we aim to recruit a total of 110 patients (55 in each group) across all centres. We anticipate that this will require a recruitment period of 6 months.

Statistical analyses
Differences between the intervention and control groups with respect to the primary outcome measure (haemoglobin level at 4 months) will be measured by comparison of the mean haemoglobin in each group, adjusted for baseline values (analysis of covariance). Data will be analysed on an intention to treat basis. For patients withdrawing before the end of the 4 month study, their haemoglobin at the time of withdrawal will be taken as their final haemoglobin. A sub-analysis will be performed to determine whether patients with significantly elevated C-reactive protein (CRP) levels (above the local laboratory's reference range) are more likely to have oxpentifylline-responsive anaemia. The data will be analysed by t-test and by repeated measures analysis of covariance. Because of power considerations and the relatively short duration of the study, no interim analysis is planned.
Secondary analyses will be performed by repeated measures analysis of covariance with and without adjustment for baseline characteristics. The analyses used for secondary outcome measures will include unpaired t-test (Key's index), Mann-Whitney U-test (ESA dosage) and chi square test (blood transfusion requirement, adverse drug reactions).

Categorical baseline characteristics (e.g. sex, race, comorbid illnesses, etc) will be summarized with the number and percent of subjects in each treatment group with the characteristic. Quantitative characteristics (e.g. age and weight) will be summarized by mean and standard deviation or median [interquartile range], depending on data distribution. The number and percent of subjects who are randomized, treated with randomized Study Drug, require intervention, prematurely discontinue, and complete the study will be summarized. Fisher's exact test or the Chi-square test will be used to assess treatment group differences in the proportions of subjects who require intervention and who complete the study. The number and percent of subjects will be summarized for each reason for premature discontinuation.

**Discussion**
This investigator-initiated, multicentre Australian and New Zealand study has been designed to provide evidence to help nephrologists and their CKD patients better determine whether Oxpentifylline (Trental®) administration will safely and effectively treat erythropoietin- or darbepoietin-resistant anaemia. Given that numerous studies have demonstrated that ESA hyporesponsive patients are at significantly increased risk of mortality [28], novel treatments for correcting anaemia in this group (such as with oxpentifylline) may represent an important strategy for improving clinical outcomes. The multicentre nature of the trial will greatly enhance its generalisability. Moreover, the trial sample size has been carefully and prospectively calculated using a minimum clinically important difference in haemoglobin level of 10 g/L and realistic estimates of trial drop-out and non-compliance rates to minimise the risk of a type 2 statistical error. Demonstration of a significant improvement in haemoglobin levels with oxpentifylline therapy will provide clinicians with an important new strategy for effectively treating ESA-resistant anaemia. On the other hand, a negative study will dissuade clinicians from unnecessarily exposing patients to oxpentifylline (which has a small potential for side effects) if it is proven to lack efficacy with respect to treating ESA-resistant anaemia.

**Abbreviations**
AKTN: Australasian Kidney Trials Network; CKD: Chronic kidney disease; CRP: C-reactive protein; CTN: Clinical trials notification; DPO: Darbepoetin; EPO: Erythropoietin; ESA: Erythropoiesis stimulating agent; ESKD: End-stage kidney disease; FPN: Ferroportin; HERO: Hemoglobin elevation in erythropoietin resistance with oxpentifylline; IFN-γ: Interferon-gamma; IL-1: Interleukin-1; IL-6: Interleukin-6; IVRS: Interactive voice response system; MedDRA: Medical dictionary for regulatory activities; SOC: System organ class; TGA: Therapeutic Goods Administration; TNF-α: Tumour necrosis factor alpha.

**Competing interests**

**Financial Competing Interests**

The study is funded by grants from the Roche Foundation for Anaemia Research (RoFAR), Amgen Australia and Janssen-Cilag.

Professor Johnson has received consultancy fees and speaker's honoraria from Sanofi-Aventis (manufacturer of oxpentifylline). He has also received consultancy fees, speaker's honoraria, research grants and conference travel sponsorships from Amgen, Janssen-Cilag and Roche (all manufacturers of erythropoiesis stimulating agents).

Dr. Hawley has received conference travel sponsorships from Amgen and Janssen-Cilag.

Professor Ferrari has received speaker's honoraria and conference travel sponsorships from Amgen, Roche and Janssen-Cilag.

Dr McDonald has received speaker's honoraria, and conference travel sponsorships from Amgen and Janssen-Cilag (manufacturers of erythropoiesis stimulating agents).

Associate Professor Alan Cass has received speaker's honoraria and research grants from Amgen, Janssen-Cilag and Roche.

The remaining authors declare that they have no financial competing interests.

**Non-Financial Competing Interests**

The authors declare that they have no non-financial competing interests.

**Authors' contributions**

DJ: Principal Investigator; conceived study; participated in design and co-ordination; helped to draft manuscript; read and approved the final manuscript. CH: Trial Management Committee member; participated in design and co-ordination; helped to draft manuscript; read and approved the final manuscript. BR: Trial Management Committee member; participated in design and co-ordi-
nation; helped to draft manuscript; read and approved the final manuscript. EB: Trial Management Committee member; participated in design and co-ordination; provided statistical advice; helped to draft manuscript; read and approved the final manuscript. CT: Trial Management Committee member; participated in design and co-ordination; provided statistical advice; helped to draft manuscript; read and approved the final manuscript. RB: Trial Management Committee member; participated in design and co-ordination; helped to draft manuscript; read and approved the final manuscript. PF: Trial Management Committee member; conceived hepcidin sub-study; participated in design and co-ordination; helped to draft manuscript; read and approved the final manuscript. SM: Trial Management Committee member; participated in design and co-ordination; helped to draft manuscript; read and approved the final manuscript. EP: Trial Management Committee member; participated in design and co-ordination; helped to draft manuscript; read and approved the final manuscript. AC: Trial Management Committee member; participated in design and co-ordination; helped to draft manuscript; read and approved the final manuscript. AE: Trial Management Committee member; conceived hepcidin sub-study; participated in design and co-ordination; helped to draft manuscript; read and approved the final manuscript.

Acknowledgements

The authors gratefully acknowledge the contributions of all members of the HERO Trial Study Group, dialysis nursing staff, trial co-investigators, research staff and patients. The invaluable assistance provided by Ms Alicia Smith, Ms Melissa Gardiner and Ms Peta-Anne Paul-Brent from the Australasian Kidney Trials Network is very much appreciated.

The study is funded by grants from the Roche Foundation for Anaemia Research (RoFAR), Amgen and Janssen-Cilag. The funding bodies played no role in the study design; collection, analysis and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication.

References

1. Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int 1996, 50:1373-1391.
2. Benz RL, Pressman MR, Hovick ET, Peterson DD: A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999, 34:1089-1095.
3. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999, 55 Suppl 69:S61-6.
4. Macdougall IC. Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002, 17 Suppl 11:S39-43.
5. Cooper AC, Mikhail A, Leithbridge MW, Kemeny DM, Macdougall IC: Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003, 14:1776-1784.
6. Fampotten JE, Brogden RN: Pentoxifylline (expentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 1995, 7:480-503.
7. Stuart J, Stone PC, Bilto YY, Keidan AJ: Oxpentifylline and ceteolit citrate improve deformability of dehydrated sickle cells. J Clin Pathol 1987, 40:1182-1186.
8. Benbennou N, Enault S, Potron G, Guenounou M: Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J Cardiovasc Pharmacol 1995, 25 Suppl 2:S73-S79.
9. Bienvenu J, Doche C, Goutowski MC, Lenoble M, Lepepe A, Perdriz JP: Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 1995, 25 Suppl 2:S80-S84.
10. Freitas JP, Filipe PM: Pentoxifylline. A hydroxyl radical scavenger. Biol Trace Elem Res 1985, 12:307-11.
11. Bellof F, Jaloustre C, Dumas P, Lacombe F, Lenoble M, Boisseau MR: Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol 1995, 25 Suppl 2:S71-574.
12. Semmler J, Gebert U, Eisenhalt T, Moeller J, Schonharting MM, Allera A, Endres S: Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 1993, 78:520-525.
13. Cooper A, Mikhail A, Leithbridge MW, Kemeny DM, Macdougall IC: Pentoxifylline inhibits cytokines that induce the synthesis of the iron regulatory hormone hepcidin. J Am Soc Nephrol 2004, 15:1877-1882.
14. Navarro JF, Mora C, Garcia J, Rivero A, Macia M, Gallego E, Mendez ML, Chahin J: Effects of pentoxifylline on the haematologic status of anaemic patients with advanced renal failure. Scand J Urol Nephrol 1999, 33:121-125.
15. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Heparin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463.
16. Nemeth E, Rivero S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
17. Park CH, Valore EV, Waring AJ, Ganz T: Pentoxifylline, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276:7806-7810.
18. Lee P, Peng H, Gelbart W, Wang L, Beutler E: Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005, 102:1906-1910.
19. Nemeth E, Turte MS, Powelton J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Heparin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
20. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003, 41:1212-1218.
21. Taes YE, Wuyts B, Boelart JR, De Vriese AS, Delanghe JR: The role of hepcidin in iron homeostasis in human pathology. Clin Chem Lab Med 2004, 42:387-389.
22. Kulaksiz H, Gehrkne SG, Janetko A, Rost D, Bruckner T, Kallinowski B, Stremmel W, Vahlteich S, Schaefer M, Kerschenobich D, Gutierrez-Ruiz MC: Pentoxifylline diminished acidophylly-induced collagen production in hepatic stellate cells by decreasing interleukin-6 expression. Pharmacol Res 2002, 46:435-443.
28. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: variables affecting this outcome predictor. *J Am Soc Nephrol* 1997, 8:1921-1929.

**Pre-publication history**
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2369/9/8/prepub